Bharat Biotech Submits Covaxin Phase 3 Trials Data to DCGI

Bharat Biotech has submitted data from phase 3 trials of the Covaxin vaccine to the Drugs Controller General of India (DCGI). Covaxin is among three vaccines being used in the nationwide drive against Covid-19. It was granted approval by the DCGI in January,



along with the Oxford University-AstraZeneca Vaccine which is being manufactured by the Pune-based Serum Institute of India (SII) as Covishield.

A third vaccine, Russia’s Sputnik V, was also granted emergency use authorisation (EUA) in April.